Huang Ruby Yun-Ju, Lin Jimmy Jin-Che
School of Medicine, College of Medicine, National Taiwan University, Taipei 10051, Taiwan
Graduate Institute of Oncology, College of Medicine, National Taiwan University, Taipei 10051, Taiwan.
Cold Spring Harb Perspect Med. 2025 Aug 1;15(8):a041315. doi: 10.1101/cshperspect.a041315.
Ovarian clear cell carcinoma (OCCC) is a histological subtype of epithelial ovarian cancer with distinct pathological features, molecular profiles, and biological functions. OCCC has high incidence rates in East Asia compared to the Western hemisphere and Europe and is associated with endometriosis. With its relative resistance to conventional treatment regimens and the worst stage-adjusted prognosis among ovarian cancer subtypes, there is an urgent need to optimize therapeutic options and to improve patient outcomes. To achieve this goal, better patient stratification strategies are required. These strategies could derive from comprehensive and in-depth multidimensional analysis of tumor heterogeneity. Understanding intertumor heterogeneity could assist us in stratifying OCCC patients based on features that are prognostic or predictive. Recent genomic, epigenomic, and transcriptomic profiling analyses allow us to provide an integrative perspective on the diverse heterogeneity in OCCC that could pave the way for novel translational research and clinical development in the future.
卵巢透明细胞癌(OCCC)是上皮性卵巢癌的一种组织学亚型,具有独特的病理特征、分子谱和生物学功能。与西半球和欧洲相比,OCCC在东亚的发病率较高,且与子宫内膜异位症相关。由于其对传统治疗方案相对耐药,且在卵巢癌亚型中分期调整后的预后最差,因此迫切需要优化治疗方案并改善患者预后。为实现这一目标,需要更好的患者分层策略。这些策略可源自对肿瘤异质性的全面深入的多维度分析。了解肿瘤间异质性有助于我们根据预后或预测特征对OCCC患者进行分层。最近的基因组、表观基因组和转录组分析使我们能够对OCCC中多样的异质性提供综合观点,这可能为未来的新型转化研究和临床发展铺平道路。